509073-67-0

Basic information

• Product Name: 3-(broMoMethyl)benzaMide
• Synonyms: 3-(broMoMethyl)benzaMide
• CAS NO: 509073-67-0
• Molecular Formula: C8H8BrNO
• Molecular Weight: 214.05922
• Mol File: 509073-67-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-(broMoMethyl)benzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(broMoMethyl)benzaMide(509073-67-0)
• EPA Substance Registry System: 3-(broMoMethyl)benzaMide(509073-67-0)

Safety Data

• Hazardous Substances Data: 509073-67-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-(BromoMethyl)benzaMide is used as a reagent in organic synthesis for its bromomethyl group, which serves as a good leaving group. This property facilitates a wide range of synthetic transformations, making it a valuable compound in the creation of various organic molecules.
Used in Pharmaceutical Industry:
3-(BromoMethyl)benzaMide is used as a building block in the development of pharmaceutical compounds. Its reactivity and ability to undergo synthetic transformations make it a useful component in the synthesis of new drug molecules.
Used in Chemical Research:
3-(BromoMethyl)benzaMide is used as a research tool in chemical studies, particularly in exploring the reactivity and properties of benzamides and their derivatives. Its unique characteristics provide insights into the behavior of similar compounds in various chemical reactions.
Safety Precautions:

Upstream product

• 618-47-3 m-toluamide 
• 620-22-4 3-Methylbenzonitrile 
• 28188-41-2 m-(bromomethyl)benzonitrile 

Downstream Products

• 1240518-75-5 C₂₆H₃₁ClN₄O₅S₂Si 
• 22517-56-2 3-<(2-Methylhydrazino)-methyl>-benzamid 

Relevant articles and documents

INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE

The present disclosure discloses compounds capable of modulating the activity of α-amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-g

A novel structural class of iminopyridine derivative 1 was identified as a potent and selective human α1D adrenoceptor (α1D adrenergic receptor; α1D-AR) antagonist against α1A- and α1B-AR through scre